Skip to main content

Axela Licenses Proteome Sciences' Brain Damage Biomarkers

NEW YORK (GenomeWeb News) – Proteome Sciences said today that it has inked a licensing deal that permits Axela to develop assays that measure Proteome Sciences' brain damage biomarkers on Axela's multiplex biomarker assay dotLab system.

The agreement includes an option for Axela to license the developed assays for research and diagnostic uses.

Cobham, UK-based Proteome Sciences has a portfolio of blood biomarkers of brain damage-related disorders it developed in a collaboration with the Biomedical Proteomics Research Group at the University of Geneva. These conditions include stroke, traumatic brain injury, subarachnoid hemorrhage, and neurodegenerative disorders such as Parkinson's, ALS, and Alzheimer's disease.

Axela CEO Rocky Ganske said in a statement that the company's technology "is particularly suited to brain injury testing where rapid and accurate quantitation of protein biomarker panels is vital."

Proteome Sciences' MS Biomarker Assay system uses the company's isobaric Tandem Mass Tags and reference materials combined with isotope dilution mass spectrometry. The firm provides biomarker discovery and validation services, as well as assay development services.

Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.